A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 4, 2010, Pages 393-397

  Fekrazad, Houman M ^a   Verschraegen, Claire F ^a,c   Royce, Melanie ^a   Smith, Harriet O ^b   Lee, Fa Chyi ^a   Rabinowitz, Ian ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Chemotherapy combination; Cyclin dependent kinase inhibitor; Flavopiridol; Phase I

Indexed keywords

ANTIEMETIC AGENT; ATROPINE; FLAVOPIRIDOL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; LOPERAMIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE; FLAVONOID; PIPERIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DYSPNEA; ELECTROLYTE DISTURBANCE; FATIGUE; FEMALE; HUMAN; HYPERCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOXIA; KIDNEY FAILURE; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; SEPSIS; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING; DOSE RESPONSE; DRUG ADMINISTRATION; LIFE EXPECTANCY; MIDDLE AGED; PATIENT SELECTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLAVONOIDS; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PATIENT SELECTION; PIPERIDINES;

EID: 77956631074     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181b2043f     Document Type: Article

References (37)

1. De Azevedo WF Jr, Mueller-Dieckmann HJ, Schulze-Gahmen U, et al. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci USA. 1996;93:2735-2740.
2. Carlson BA, Dubay MM, Sausville EA, et al. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 1996;56:2973-2978.
3. Sedlacek HH. Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol. 2001;38:139-170.
4. Jager W, Zembsch B, Wolschann P, et al. Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver. Life Sci. 1998;62:1861-1873.
5. Carlson B, Lahusen T, Singh S, et al. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res. 1999;59:4634-4641.
6. Melillo G, Sausville EA, Cloud K, et al. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res. 1999;59:5433-5437.
7. Worland PJ, Kaur G, Stetler-Stevenson M, et al. Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells: Correlation with decreased H1 kinase activity. Biochem Pharmacol. 1993;46:1831-1840.
8. Li Y, Bhuiyan M, Alhasan S, et al. Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol. Clin Cancer Res. 2000;6:223-229.
9. Drees M, Dengler WA, Roth T, et al. Flavopiridol (L86-8275): Selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res. 1997;3:273-279.
10. Stadler WM, Vogelzang NJ, Amato R, et al. Flavopiridol, a novel cyclindependent kinase inhibitor, in metastatic renal cancer: A University of Chicago Phase II Consortium study. J Clin Oncol. 2000;18:371-375.
11. Schwartz GK, Ilson D, Saltz L, et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol. 2001;19:1985-1992.
12. Shapiro GI, Supko JG, Patterson A, et al. A phase II trial of the cyclindependent kinase inhibitor flavopiridol in patients with previously untreated stage IV nonsmall cell lung cancer. Clin Cancer Res. 2001;7:1590-1599.
13. Byrd JC, Peterson BL, Gabrilove J, et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: Results from Cancer and Leukemia Group B study 19805. Clin Cancer Res. 2005;11:4176-4181.
14. Arguello F, Alexander M, Sterry JA, et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood. 1998;91:2482-2490.
15. Senderowicz AM. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms. Cancer Chemother Pharmacol. 2003;52(suppl 1):S61-S73.
16. Jung CP, Motwani MV, Schwartz GK. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res. 2001;7:2527-2536.
17. Motwani M, Jung C, Sirotnak FM, et al. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res. 2001;7:4209-4219.
18. Matranga CB, Shapiro GI. Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase. Cancer Res. 2002;62:1707-1717.
19. Motwani M, Sirotnak FM, She Y, et al. Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells. Cancer Res. 2002;62:3950-3955.
20. Bible KC, Kaufmann SH. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration. Cancer Res. 1997;57:3375-3380.
21. Takatani H, Soda H, Nakamura Y, et al. Phase I study of irinotecan and gemcitabine in previously untreated patients with advanced nonsmall cell lung cancer. Jpn J Clin Oncol. 2007;37:353-357.
22. Rudek MA, Bauer KS Jr, Lush RM III, et al. Clinical pharmacology of flavopiridol following a 72-hour continuous infusion. Ann Pharmacother. 2003;37:1369-1374.
23. Senderowicz AM, Headlee D, Stinson SF, et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol. 1998;16:2986-2999.
24. Thomas JP, Tutsch KD, Cleary JF, et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol. 2002;50:465-472.
25. Messmann RA, Ullmann CD, Lahusen T, et al. Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6. Clin Cancer Res. 2003;9:562-570.
26. Tan AR, Headlee D, Messmann R, et al. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol. 2002;20:4074-4082.
27. Van Veldhuizen PJ, Faulkner JR, Lara PN Jr, et al. A phase II study of flavopiridol in patients with advanced renal cell carcinoma: Results of Southwest Oncology Group Trial 0109. Cancer Chemother Pharmacol. 2005;56: 39-45.
28. Phelps MA, Lin TS, Johnson AJ, et al. Clinical response and pharmacokinetics from a phase I study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood. 2009;113:2637-2645.
29. Lin T, Heerema N, Lozanski G, et al. Flavopiridol (Alvocidib) induces durable responses in relapsed chronic lymphocytic leukemia (CLL) patients with high-risk cytogenetic abnormalities. 2008;112:23-24.
30. Schwartz GK, O'Reilly E, Ilson D, et al. Phase I study of the cyclindependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol. 2002;20:2157-2170.
31. Rocha Lima CM, Savarese D, Bruckner H, et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol. 2002; 20:1182-1191.
32. Stathopoulos GP, Syrigos K, Aravantinos G, et al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer. 2006;95:587-592.
33. Yip D, Goldstein D. Adding irinotecan to first-line gemcitabine improves tumour response in advanced pancreatic cancer. Cancer Treat Rev. 2005;31: 236-241.
34. Moulder S, Valkov N, Neuger A, et al. Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response. Cancer. 2008;113:2646-2654.
35. Bhargava P, Jani CR, Savarese DM, et al. Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: Preliminary report. Oncology (Williston Park). 2003;17(suppl 8):23-26.
36. Shah MA, Kortmansky J, Motwani M, et al. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res. 2005;11:3836-3845.
37. Goffin J, Appleman L, Ryan D, et al. A phase I trial of gemcitabine followed by flavopiridol in patients with solid tumors. Lung Cancer. 2003;41:S179.